REPORT HIGHLIGHTS
-
The market for anti-inflammatory drugs to treat the diseases covered in this report was approximately $21.9 billion in 2005 and is projected to increase to $35.5 billion in 2010.
-
The fastest growing disease category for anti-inflammatory treatment is psoriasis, which saw the first introductions of expensive monoclonal antibody products in the last two years.
-
The largest market by far in 2005 is that for the treatment of asthma and chronic obstructive pulmonary disease, which accounted for approximately 36% of the total market in 2005. The asthma/COPD market will remain the largest in 2010, but will decline to 31.4% of the total of market by the end of the forecast period.
REPORT SCOPE
The anti-inflammatory products market was dramatically shaken in September 2004 with the withdrawal from the marketplace of Merck's multibillion-dollar anti-inflammatory drug Vioxx. This was followed by the withdrawal of another cyclooxygenase-2 (COX-2) inhibiting anti-inflammatory product, Pfizer's Bextra, from the American, Canadian and European markets in April 2005. This left only one COX-2 inhibitor, Pfizer's Celebrex, on the U.S. market. Following the removal of Vioxx, the U.S. Food and Drug Administration (FDA) enhanced its scrutiny of this class of drugs and required black-box warnings to be placed on all similar prescription and nonprescription nonsteroidal anti-inflammatory drugs (NSAIDs).
This comprehensive study:
- Analyzes and assesses marketed and in-development prescription, systemic anti-infl ammatory drugs indicated for the following diseases-ankylosing spondylitis, asthma/chronic obstructive pulmonary disease (COPD), infl ammatory bowel diseases, multiple sclerosis, psoriasis and rheumatoid arthritis.
- Provides an overview of the categories of anti-inflammatory drugs, including biological anti-inflammatory products, their methods of activity, usage and sales. Markets for antiinfl ammatory drugs by disease, including sales and forecasts as well as discussion of products for each indication that are in Phase II and later trials.
- Discusses industry structure including the impact of the removal of Vioxx and Bextra from the marketplace. Also discussed is the issue of direct-to-consumer (DTC) marketing.
- Profiles companies emphasizing leaders in the pharmaceutical and biotechnology industry in the research and development of anti-inflammatory drugs and the innovative products they have launched or have in development.
The base year for this study is 2005. Figures are based on revenue figures at the manufacturers' level and are projected in 2005 constant dollars; that is, inflation is not computed into the projection figures.
Information to prepare this study was derived from information obtained from product managers, marketing strategists, research executives and others at leading pharmaceutical and biotechnology companies that compete in the market for anti-inflammatory drugs or that have products in development for this market.
The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from the business literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals.
Lynn Gray has been a research analyst in the biotechnology and life sciences since 1989. Her collaboration with BCC Research began in 1996, and during that time she has authored over 20 BCC biomedical reports.
